Evaluation of the BACTEC MGIT 960 system and the resazurin microtiter assay for susceptibility testing of Mycobacterium tuberculosis to second-line drugs.

J Microbiol Methods

Núcleo de Tuberculose e Micobacterioses, Centro de Bacteriologia, Instituto Adolfo Lutz, Av. Dr. Arnaldo, 351 - 9° andar, 01246-902 São Paulo, SP, Brazil.

Published: August 2017

Drug resistance in tuberculosis is a major threat to public health and control of the disease worldwide. Given the need of a rapid and accurate detection of Mycobacterium tuberculosis resistance to second-line drugs, this study evaluated the performance of the BACTEC MGIT 960 for second-line, drug susceptibility testing in comparison with the resazurin microtiter assay (REMA), in order to implement the automated methodology in the diagnostic routine of a reference laboratory. Drug susceptibility testing (DST) for second-line drugs of 151 MDR M. tuberculosis clinical isolates was performed by both BACTEC MGIT 960 and REMA, and a panel of 26 M. tuberculosis reference isolates from a proficiency test was tested by the BACTEC MGIT 960. DST for second-line drugs by the BACTEC MGIT 960 system was more rapid, highly reproducible and showed 100% of proficiency. After these results, this methodology was successfully implemented in our diagnostic routine for all MDR-TB patients.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.mimet.2017.06.007DOI Listing

Publication Analysis

Top Keywords

bactec mgit
20
mgit 960
20
second-line drugs
16
susceptibility testing
12
960 system
8
resazurin microtiter
8
microtiter assay
8
mycobacterium tuberculosis
8
drug susceptibility
8
diagnostic routine
8

Similar Publications

The epidemiology and gene mutation characteristics of pyrazinamide-resistant clinical isolates in Southern China.

Emerg Microbes Infect

January 2025

State Key Laboratory of Respiratory Disease, Guangzhou Key Laboratory of Tuberculosis Research, Department of Tuberculosis, Guangzhou Chest Hospital, Institute of Tuberculosis, Guangzhou Medical University, Guangdong, 510095, P.R. China.

This study investigates the epidemic trend of pyrazinamide (PZA)-resistant tuberculosis in Southern China over 11 years (2012-2022) and evaluates the mutation characteristics of PZA resistance-related genes ( and ) in clinical () isolates. To fulfil these goals, we analyzed the phenotypic PZA resistance characteristics of 14,927 clinical isolates for which Bactec MGIT 960 PZA drug susceptibility testing (DST) results were available, revealing that 2,054 (13.76%) isolates were resistant to PZA.

View Article and Find Full Text PDF

The material for drug resistance testing was 28 strains of Mycobacterium caprae isolated from tissue collected post mortem from a free-living Bieszczady Mountain European bison (Bison bonasus caucasicus) herd. All drug susceptibility tests were carried out on an automated Bactec mycobacterial growth indicator tube (MGIT) 960 system, using Bactec MGIT 960 streptomycin, isoniazid, rifampin and ethambutol (S.I.

View Article and Find Full Text PDF

Mycobacterium tuberculosis is a human pathogen that causes Tuberculosis (TB) disease. Researchers have reported the activity of traditional medicinal plants against human pathogens. However, antimycobacterial studies of medicinal plants against M.

View Article and Find Full Text PDF

Analysis of Time-to-Positivity Data in Tuberculosis Treatment Studies: Identifying a New Limit of Quantification.

Int J Antimicrob Agents

December 2024

UCSF Center for Tuberculosis, University of California, San Francisco, San Francisco, California, USA; Division of Pulmonary and Critical Care Medicine, University of California, San Francisco, San Francisco, California, USA.

Background: The BACTEC Mycobacteria Growth Indicator Tube (MGIT) machine is the standard globally for detecting viable mycobacteria in patients' sputum. Samples are observed for no longer than 42 days, at which point the sample is declared 'negative' for tuberculosis (TB). This time to detection of bacterial growth, referred to as time-to-positivity (TTP), is increasingly of interest, not solely as a diagnostic tool but also as a continuous biomarker wherein change in TTP can be used for comparing the bactericidal activity of different TB treatments.

View Article and Find Full Text PDF

A simplified pyrazinamidase test for pyrazinamide antimicrobial susceptibility testing.

J Clin Microbiol

December 2024

Tuberculosis Research Center, Centers for Disease Control, Ministry of Health and Welfare, Taipei, Taiwan.

Unlabelled: Pyrazinamide (PZA) is an important first-line drug for tuberculosis (TB) treatment by eradicating the persisting complex (MTBC). Due to cost and technical challenges, end TB strategies are hampered by the lack of a simple and reliable culture-based PZA antimicrobial susceptibility testing (AST) for routine use. We initially developed a simplified chromogenic pyrazinamidase (PZase) test in the TB reference laboratory using a training set MTBC isolates with various drug-resistant profiles, and validated its performance using consecutive BACTEC MGIT 960 (MGIT)-culture-positive culture in 10 clinical laboratories.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!